In vitro dissolution and oral bioavailability study of fenofibrate nanomatrix system prepared by hot-melt extrusion

doi:10.5246/jcps.2019.05.032

Abstract

Abstract:

Solvent evaporation method for preparation of nanomatrix has the disadvantages, such as residual organic solvent, environmental pollution, explosion-proofing and so on. To overcome these shortcomings, a series of fenofibrate nanomatrix drug delivery system (NDDS) consisting of nano-porous silica Sylysia^®350 (S350) and pH sensitive material Eudragit^®L100-55 (EL100-55) were prepared using hot-melt extrusion (HME), and their in vitro dissolution and in vivo bioavailability were compared. Finally, the formulation with the highest in vivo bioavailability was selected as the optimized formulation for DSC and PXRD characterization. The results showed that the optimized NDDS showed a higher bioavailability than the reference formulation, although there was crystalline form drug remaining in NDDS. The relative bioavailability of the optimized formulation was 157.1% compared with the commercial product Lipanthyl^®. In addition, the relative bioavailability of the optimized formulation was 124.8% in comparison with the formulation prepared by solvent evaporation method, showing that the NDDS prepared by the HME method was effective in improving the bioavailability of fenofibrate. In conclusion, HME was a promising method to prepare NDDS.

Key words: Nanomatrix drug delivery system, Hot-melt extrusion, Fenofibrate, Dissolution, Bioavailability

CLC Number:

R944

Supporting:

Yajie Yin, Xiaofei Zhang, Zheng Cui, Wei Qu, Bing He, Wenbing Dai, Hua Zhang, Xueqing Wang, Qiang Zhang. In vitro dissolution and oral bioavailability study of fenofibrate nanomatrix system prepared by hot-melt extrusion[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(5): 329-338.

References

[1] Salama, N.N.; Eddington, N.D.; Fasano, A. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 2006, 58, 15-28.

[2] Brewster, M.E.; Loftsson, T. Cyclodextrins as pharma-ceutical solubilizers. Adv. Drug Deliv. Rev. 2007, 59, 645-666.

[3] Mellaerts, R.; Mols, R.; Kayaert, P.; Annaert, P.; Van Humbeeck, J.; Van den Mooter, G.; Martens, J.A.; Augustijns, P. Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport. Int. J. Pharm. 2008, 357, 169-179.

[4] Jain, S.K.; Awasthi, A.M.; Jain, N.K.; Agrawal, G.P. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: Preparation and in vitro characterization. J. Controlled Release. 2005, 107, 300-309.

[5] Rojtanatanya, S.; Pongjanyakul, T. Propranolol-magnesium aluminum silicate complex dispersions and particles: characterization and factors influencing drug release. Int. J. Pharm. 2010, 383, 106-115.

[6] Dai, J.D.; Nagai, T.; Wang, X.Q.; Zhang, T.; Meng, M.; Zhang, Q. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int. J. Pharm. 2004, 280, 229-240.

[7] Wang, X.Q.; Dai, J.D.; Chen, Z.; Zhang, T.; Xia, G.M.; Nagai, T.; Zhang, Q. Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. J. Controlled. Release. 2004, 97, 421-429.

[8] Wu, C.S.; Wang, X.Q.; Meng, M.; Li, M.G.; Zhang, H.; Zhang, X.; Wang, J.C.; Wu, T.; Nie, W.H.; Zhang, Q. Effects of pH-sensitive nanoparticles prepared with different polymers on the distribution, adhesion and transition of Rhodamine 6G in the gut of rats. J. Microencapsul. 2010, 27, 205-217.

[9] Miller, D.A.; DiNunzio, J.C.; Yang, W.; McGinity, J.W.; Williams, R.O. 3rd Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm. Res. 2008, 25, 1450-1459.

[10] Jia, Z.R. Studies on nano-matrix solid oral drug delivery system for water insoluble drug-fenofibrate. Diss, 2011.

[11] Jia, Z.R.; Lin, P.; Xiang, Y.; Wang, X.Q.; Wang, J.C.; Zhang, X.; Zhang, Q. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate. Eur. J. Pharm. Biopharm. 2011, 79, 126-134.

[12] Nakamichi, K.; Yasuura, H.; Fukui, H.; Oka, M.; Izumi, S. Evaluation of a floating dosage form of nicardipine hydrochloride and hydroxypropylmethylcellulose acetate succinate prepared using a twin-screw extruder. Int. J. Pharm. 2001, 218, 103-112.

[13] Tiwari, R.; Agarwal, S.K.; Murthy, R.S.R.; Tiwari, S. Formulation and evaluation of sustained release extrudes prepared via novel hot melt extrusion technique. J. Pharm. Innov. 2014, 9, 246-258.

[14] Breitenbach, J. Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 2002, 54, 107-117.

[15] Ramos, A.J.; Hernández, E.; Plá-Delfina, J.M.; Merino, M. Intestinal absorption of zearalenone and in vitro study of non-nutritive sorbent materials. Int. J. Pharm. 1996, 128, 129-137.

[16] Follonier, N.; Doelker, E.; Cole, E.T. Various ways of modulating the release of diltiazem hydrochloride from hot-melt extruded sustained release pellets prepared using polymeric materials. J. Controlled Release. 1995, 36, 243-250.

[17] Repka, M.A.; Battu, S.K.; Upadhye, S.B.; Thumma, S.; Crowley, M.M.; Zhang, F.; Martin, C.; McGinity, J.W. Pharmaceutical applications of hot-melt extrusion: part II. Drug Dev. Ind. Pharm. 2007, 33, 1043-1057.

[18] Repka, M.A.; McGinity, J.W. Physical-mechanical, moisture absorption and bioadhesive properties of hydroxypropylcellulose hot-melt extruded films. Biomaterials. 2000, 21, 1509-1517.

[19] Guns, S.; Dereymaker, A.; Kayaert, P.; Mathot, V.; Martens, J.A.; Van den Mooter, G. Comparison between hot-melt extrusion and spray-drying for manufacturing solid dispersions of the graft copolymer of ethylene glycol and vinylalcohol. Pharm. Res. 2011, 28, 673-682.

[20] Fu, J.J.; Zhang, L.L.; Guan, T.T.; Tang, X.; He, H.B. Stable nimodipine tablets with high bioavailability containing NM-SD prepared by hot-melt extrusion. Powder Technol. 2010, 204, 214-221.

[21] Zheng, X.; Yang, R.; Zhang, Y.; Wang, Z.J.; Tang, X.; Zheng, L.Y. Part II: bioavailability in beagle dogs of nimodipine solid dispersions prepared by hot-melt extrusion. Drug Dev. Ind. Pharm. 2007, 33, 783-789.

[22] Heinz, A.; Gordon, K.C.; McGoverin, C.M.; Rades, T.; Strachan, C.J. Understanding the solid-state forms of fenofibrate:a spectroscopic and computational study. Eur. J. Pharm. Biopharm. 2009, 71, 100-108.

[23] Buch, P.; Langguth, P.; Kataoka, M.; Yamashita, S. IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system. J. Pharm. Sci. 2009, 98, 2001-2009.

[24] Hanafy, A.; Spahn-Langguth, H.; Vergnault, G.; Grenier, P.; Tubic Grozdanis, M.; Lenhardt, T.; Langguth, P. Pharma-cokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv. Drug Deliv. Rev. 2007, 59, 419-426.

[25] Maghsoodi, M. Physicomechanical properties of naproxen-loaded microparticles prepared from Eudragit l100. AAPS PharmSciTech. 2009, 10, 120-128.